A handful of biotechs are asking a next-generation question ... that we're modifying to turn into CAR-T cells.” There’s also early evidence that in vivo CARs are less likely to cause cytokine ...

Modifying T cells before activation and expanding them in vitro may lead to more effective and safer immunotherapy treatments. If the challenges associated with resting T cell transfection can be ...

Third-generation CAR T-cell therapy shows promising efficacy and safety in heavily pretreated CLL patients, with a 67% complete response rate. The new CAR T-cell generation aims to mitigate ...

Through this collaboration, we are pioneering innovative scientific advancements that have the potential to redefine the future of cell therapy.” ESO-T01 is the first in vivo BCMA CAR-T candidate to ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to be dosed in a human clinical trial, and has been developed by EsoBiotec using its third-generation immune-shielded cell specific lentiviral ...

(Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced the closing of a $100 million Series C financing.

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics, a leading cell and gene therapy statrtup ...

“Research conducted at Penn demonstrates the tremendous promise of harnessing mRNA and targeted LNP delivery to train a patient’s body to make CAR-T cells in vivo, potentially creating new ...